Related Experiment Video
Updated: Aug 17, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Medicare program; competitive acquisition of outpatient drugs and biologicals under Part B. Interim final rule with
Abstract:
This interim final rule with comment period implements provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 that require the implementation of a competitive acquisition program for certain Medicare Part B drugs not paid on a cost or prospective payment system basis. Beginning January 1, 2006, physicians will generally be given a choice between obtaining these drugs from vendors selected through a competitive bidding process or directly purchasing these drugs and being paid under the average sales price system.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Biopharmaceutics and Pharmacokinetics: Overview
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Dosage Regimens: Partial Pharmacokinetic Parameters